Programme

 

Glasgow Programme – Thursday 15th November 2018
12.00 Arrivals & badge collection
12:30 – 13:15 Buffet Lunch
13:15 – 13:20 Welcome, introductions & agenda
Karen Campbell (Chair)
Macmillan Associate Professor, Edinburgh Napier University
13:20 – 14:05 Background underpinning the basic biology of CLL & lymphomas and their cellular processes
Dr Verna Lavender
Head of Guy’s Cancer Academy, Guy’s and St. Thomas’ Hospital NHS Foundation Trust
14:05 – 14:50 Novel strategies & paradigm shifts in the R/R CLL treatment pathway
Dr Angus Broom
Consultant Haematologist, The Western General Hospital, Edinburgh
14:50 – 15:35 Trials data for Hodgkin’s and non-Hodgkin’s lymphoma
Dr Pam McKay
Consultant Haematologist, Beatson West of Scotland Cancer Centre, Glasgow
15:35 – 16:00 Break
16:00 – 16:45 Safety & hazard management: patients at risk of toxicities, triage pathways and policies management
Asha Mathew
Advance Nurse Practitioner in Haematology & Team Lead, Cancer Care & Haematology, Buckinghamshire NHS Trust
16:45 – 17:30 A trio of patient case studies – targeted therapies in CLL, FL & Hodgkin’s lymphoma
Karen Stanley
Haematology Advanced Nurse Practitioner, Guys Hospital, London
Jackie Green
Consultant Nurse, Croydon Hospital
17:30 – 17:40 Learning outcomes & key takeaways
Karen Campbell (Chair)
Macmillan Associate Professor, Edinburgh Napier University
17:40 – 18:30 Coffee & networking
18:30 Close

 

ONC/UK/19-03/PMAR/1117f(1)
Date of preparation: June 2019

This activity is intended for medical Haematology/Oncology healthcare professionals, scientists and academics involved in the management of, and research into CAR T-cell therapy in patients with high-grade lymphoid malignancies, specifically relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), as well as those with interest in the wider treatment landscape of haematological malignancies. Data on licensed CAR-T products will be presented.